Truist analyst Robyn Karnauskas downgraded Fate Therapeutics to Hold from Buy with a price target of $7, down from $46.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FATE:
- Here’s Why Fate Therapeutics (NASDAQ:FATE) Stock Is Sliding Down
- Fate Therapeutics down 45% on termination of collaboration pact with Janssen
- Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
- Fate Therapeutics initiated with a Buy at EF Hutton
- Fate Therapeutics downgraded to Neutral from Buy at Guggenheim